Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells

Czolk,Rebecca; Schwarz,Niklas; Koch,Henner; Schötterl,Sonja; Wuttke,Thomas   V.; Holm,Per   S.; Huber,Stephan   M.; Naumann,Ulrike

doi:10.3892/ijmm.2019.4296

Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells

Authors:
- Rebecca Czolk
- Niklas Schwarz
- Henner Koch
- Sonja Schötterl
- Thomas V. Wuttke
- Per S. Holm
- Stephan M. Huber
- Ulrike Naumann
View Affiliations

Affiliations: Department of Vascular Neurology, Laboratory for Molecular Neuro‑Oncology, Hertie Institute for Clinical Brain Research, Tübingen NeuroCampus, University of Tübingen, D‑72076 Tübingen, Germany, Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, Tübingen NeuroCampus, University of Tübingen, D‑72076 Tübingen, Germany, Department of Neurosurgery, University Hospital Tübingen, D‑72076 Tübingen, Germany, Department of Urology, Hospital ‘Rechts der Isar’, Technical University of Munich, D‑81675 Munich, Germany, Department of Radiation Oncology, University Hospital Tübingen, D‑72076 Tübingen, Germany
Published online on: July 31, 2019 https://doi.org/10.3892/ijmm.2019.4296
Pages: 1484-1494
Copyright: © Czolk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Virotherapy using oncolytic viruses is an upcoming therapy strategy for cancer treatment. A variety of preclinical and clinical trials have indicated that adenoviruses may be used as potent agents in the treatment of a variety of cancers, and also for the treatment of brain tumors. In these studies, it has also been shown that oncovirotherapy is safe in terms of toxicity and side effects. In addition, previous studies have presented evidence for a significant role of oncovirotherapy in the activation of anti‑tumor immune responses. With regard to oncolytic adenoviruses, we have demonstrated previously that the multifunctional protein Y‑box binding protein‑1 (YB‑1) is a potent factor that was used to develop an YB‑1‑dependent oncolytic adenovirus (XVir‑N‑31). XVir‑N‑31 provides the opportunity for tumor‑selective replication and exhibited marked oncolytic properties in a mouse glioma tumor model using therapy‑resistant brain tumor initiating cells (BTICs). In a number of, but not all, patients with glioma, YB‑1 is primarily located in the nucleus; this promotes XVir‑N‑31‑replication and subsequently tumor cell lysis. However, in certain BTICs, only a small amount of YB‑1 has been identified to be nuclear, and therefore virus replication is suboptimal. YB‑1 in BTICs was demonstrated to be translocated into the nucleus following irradiation, which was accompanied by an enhancement in XVir‑N‑31 production. R28 glioma spheres implanted in living organotypic human brain slices exhibited a significantly delayed growth rate when pre‑irradiated prior to XVir‑N‑31‑infection as compared with single treatment methods. Consistent with the in vitro data, R28 glioma‑bearing mice exhibited a prolonged mean and median survival following single tumor irradiation prior to intratumoral XVir‑N‑31 injection, compared with the single treatment methods. In conclusion, the present study demonstrated that in an experimental glioma model, tumor irradiation strengthened the effect of an XVir‑N‑31‑based oncovirotherapy.

View Figures

View References

1	Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
2	Auffinger B, Spencer D, Pytel P, Ahmed AU and Lesniak MS: The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother. 15:741–752. 2015. View Article : Google Scholar : PubMed/NCBI
3	Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, Lesniak MS and Ahmed AU: Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 21:1119–1131. 2014. View Article : Google Scholar : PubMed/NCBI
4	Molina JR, Hayashi Y, Stephens C and Georgescu MM: Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia. 12:453–463. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A and Kitanaka C: Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells. 28:1930–1939. 2010. View Article : Google Scholar : PubMed/NCBI
6	Toulany M, Schickfluss TA, Eicheler W, Kehlbach R, Schittek B and Rodemann HP: Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 13:R282011. View Article : Google Scholar : PubMed/NCBI
7	Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, Bosserhoff A and Schittek B: MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol. 21:265–270. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lee Wu J, Yokom C, Jiang D, Cheang H, Yorida MC, Turbin E, Berquin D, Mertens IM, Iftner PRT, et al: Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 66:4872–4879. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kosnopfel C, Sinnberg T and Schittek B: Y-box binding protein 1-a prognostic marker and target in tumour therapy. Eur J Cell Biol. 93:61–70. 2014. View Article : Google Scholar : PubMed/NCBI
10	Schittek B, Psenner K, Sauer B, Meier F, Iftner T and Garbe C: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 120:2110–2118. 2007. View Article : Google Scholar : PubMed/NCBI
11	Alemasova EE, Pestryakov PE, Sukhanova MV, Kretov DA, Moor NA, Curmi PA, Ovchinnikov LP and Lavrik OI: Poly(ADP-ribosyl)ation as a new posttranslational modification of YB-1. Biochimie. 119:36–44. 2015. View Article : Google Scholar : PubMed/NCBI
12	Tiwari A, Rebholz S, Maier E, Dehghan Harati M, Zips D, Sers C, Rodemann HP and Toulany M: Stress-induced phosphorylation of nuclear YB-1 depends on nuclear trafficking of p90 ribosomal S6 kinase. Int J Mol Sci. 19:pii: E24412018. View Article : Google Scholar
13	Ewert L, Fischer A, Brandt S, Scurt FG, Philipsen L, Müller AJ, Girndt M, Zenclussen AC, Lindquist JA, Gorny X and Mertens PR: Cold shock Y-box binding protein-1 acetylation status in monocytes is associated with systemic inflammation and vascular damage. Atherosclerosis. 278:156–165. 2018. View Article : Google Scholar : PubMed/NCBI
14	Pagano C, di Martino O, Ruggiero G, Maria Guarino A, Mueller N, Siauciunaite R, Reischl M, Simon Foulkes N, Vallone D and Calabrò V: The tumor-associated YB-1 protein: New player in the circadian control of cell proliferation. Oncotarget. 8:6193–6205. 2017. View Article : Google Scholar :
15	Lage H, Surowiak P and Holm PS: YB-1 as a potential target in cancer therapy. Pathologe. 2(Suppl 2): S187–S190. 2008.In German. View Article : Google Scholar
16	Holm PS, Bergmann S, Jurchott K, Lage H, Brand K, Ladhoff A, Mantwill K, Curiel DT, Dobbelstein M, Dietel M, et al: YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem. 277:10427–10434. 2002. View Article : Google Scholar : PubMed/NCBI
17	Holm PS, Lage H, Bergmann S, Jürchott K, Glockzin G, Bernshausen A, Mantwill K, Ladhoff A, Wichert A, Mymryk JS, et al: Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: Impact for cancer gene therapy. Cancer Res. 64:322–328. 2004. View Article : Google Scholar : PubMed/NCBI
18	Mantwill K, Naumann U, Seznec J, Girbinger V, Lage H, Surowiak P, Beier D, Mittelbronn M, Schlegel J and Holm PS: YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Transl Med. 11:2162013. View Article : Google Scholar : PubMed/NCBI
19	Bieler A, Mantwill K, Holzmüller R, Jürchott K, Kaszubiak A, Stärk S, Glockzin G, Lage H, Grosu AL, Gansbacher B and Holm PS: Impact of radiation therapy on the oncolytic adenovirus dl520: Implications on the treatment of glioblastoma. Radiother Oncol. 86:419–427. 2008. View Article : Google Scholar
20	Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP: CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
21	Verhoog MB, Goriounova NA, Obermayer J, Stroeder J, Hjorth JJ, Testa-Silva G, Baayen JC, de Kock CP, Meredith RM and Mansvelder HD: Mechanisms underlying the rules for associative plasticity at adult human neocortical synapses. J Neurosci. 33:17197–17208. 2013. View Article : Google Scholar : PubMed/NCBI
22	Schwarz N, Hedrich UBS, Schwarz H, P A H, Dammeier N, Auffenberg E, Bedogni F, Honegger JB, Lerche H, Wuttke TV and Koch H: Human Cerebrospinal fluid promotes long-term neuronal viability and network function in human neocortical organotypic brain slice cultures. Sci Rep. 7:122492017. View Article : Google Scholar : PubMed/NCBI
23	Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al: Fiji: An open-source platform for biological-image analysis. Nat Methods. 9:676–682. 2012. View Article : Google Scholar : PubMed/NCBI
24	Erhardt W, Henke J and Haberstroh J: Anästhesie und Analgesie beim klein-und heimtier. Schattauer Verlag; 2004
25	Mutschelknaus L, Azimzadeh O, Heider T, Winkler K, Vetter M, Kell R, Tapio S, Merl-Pham J, Huber SM, Edalat L, et al: Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci Rep. 7:124232017. View Article : Google Scholar : PubMed/NCBI
26	Zheng J, Dong W, Zhang J, Li G and Gong H: YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients. Acta Biochim Biophys Sin (Shanghai). 48:318–325. 2016. View Article : Google Scholar
27	Tong H, Zhao K, Zhang J, Zhu J and Xiao J: YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway. Drug Des Devel Ther. 13:317–326. 2019. View Article : Google Scholar : PubMed/NCBI
28	Wu J, Stratford AL, Astanehe A and Dunn SE: YB-1 is a transcription/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. transl Oncogenomics. 2:49–65. 2007.PubMed/NCBI
29	Wild-Bode C, Weller M, Rimner A, Dichgans J and Wick W: Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma. Cancer Res. 61:2744–2750. 2001.PubMed/NCBI
30	Khan L, Soliman H, Sahgal A, Perry J, Xu W and Tsao MN: External beam radiation dose escalation for high grade glioma. Cochrane Database Syst Rev. 19:CD0114752016.
31	Woller N, Gürlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM, Saborowski M, Geffers R, Manns MP, Wirth TC, et al: Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther. 23:1630–1640. 2015. View Article : Google Scholar : PubMed/NCBI
32	Sahebjam S, Sharabi A, Lim M, Kesarwani P and Chinnaiyan P: Immunotherapy and radiation in glioblastoma. J Neurooncol. 134:531–539. 2017. View Article : Google Scholar : PubMed/NCBI